Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.

NCT Number	NCT07764978
Lead Sponsor	AstraZeneca
Conditions	Newly Diagnosed Multiple Myeloma
Enrollment	750 participants
Start Date	2026-06-26
Primary Completion	2029-01-11 (estimated)
Study Completion	2034-05-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-14